Martin Shkreli, the reviled former drug company entrepreneur, may face yet more charges in a securities fraud investigation, his defense attorneys revealed at a hearing on Tuesday in New York city.
Shkreli became infamous when his former drug company Turing purchased the patent for Daraprim, a drug that can make the difference between life and death for some patients with HIV, and boosted the price to $750 a pill.
In December, he was ousted from his own company after being arrested on charges of securities fraud and insider trading. The charges – which he denies – are unrelated to the Daraprim controversy. The new charges may relate to another drug company the 33-year-old ran.
On Tuesday, Shkreli attended a hearing before US district judge Kiyo Matsumoto where his attorneys asked that he be given further time in case additional charges were filed, according to Bloomberg News. The government may prosecute Shkreli for defrauding shareholders over the distribution of shares in another pharmaceutical company Shkreli ran, Retrophin.
Shkreli’s social media presence has been defiant throughout his public disgrace, and on Tuesday, his Twitter feed was no exception: “How much spaghetti can you throw at a wall in an attempt to see what sticks? Asking for a friend...”
US attorney Winston Paes told Shkreli and his counsel that an additional indictment might be filed as soon as next month. The new charges, should they be filed, probably relate to allegations that Shkreli paid off investors who had lost money in his hedge funds with cash from Retrophin. The lawyer involved with Shkreli’s Turing dealings, Evan Greebel, is involved with the Retrophin controversy as well. Shkreli’s next court date is 6 June.
This article was written by Sam Thielman in New York, for theguardian.com on Tuesday 3rd May 2016 20.06 Europe/Londonguardian.co.uk © Guardian News and Media Limited 2010